Table 3.
Cox regression analysis for the primary endpoint
|
Cox regression analysis Combined events |
Univariate | Multivariate | ||
|---|---|---|---|---|
|
Hazard ratio 95% CI |
P‐value | |||
| Age | 1.01 [0.98; 1.04] | 0.58 | ||
| Female | 1.46 [0.94; 2.28] | 0.088 | ||
| Body mass index | 0.97 [0.94; 1.01] | 0.10 | ||
| Mean blood pressure | 0.99 [0.98; 1.01] | 0.31 | ||
| NYHA functional classes III and IV | 1.58 [1.03; 2.41] | 0.037 | ||
| Cardiovascular risk factors | ||||
| Diabetes | 1.65 [1.08; 2.52] | 0.022 | ||
| Medical history | ||||
| Atrial fibrillation | 1.25 [0.80; 1.95] | 0.33 | ||
| Ischaemic cardiomyopathy | 0.93 [0.60; 1.45] | 0.76 | ||
| Medication | ||||
| Loop diuretic | 2.16 [1.25; 3.72] | 0.005 | ||
| Thiazide | 0.55 [0.30; 0.99] | 0.048 | ||
| Mineralocorticoid receptor antagonist | 1.38 [0.85; 2.15] | 0.20 | ||
| Beta‐blocker | 0.97 [0.62; 1.52] | 0.90 | ||
| ACEI or ARB | 0.90 [0.57;1.40] | 0.63 | ||
| Oral anticoagulant | 1.46 [0.95; 2.27] | 0.088 | ||
| Biology | ||||
| Haemoglobin (g/dL) | 0.86 [0.76;0.97] | 0.013 | ||
| GFR (mL/min/1.73 m2) by CKD‐EPI | 0.98 [0.97; 0.99] | <0.001 | ||
| NT‐proBNP (pg/mL) | 1.19 [0.97; 1.46] | 0.10 | ||
| Hs TnT (pg/mL) | 1.70 [1.25; 2.30] | 0.001 | ||
| Iron (ug/dL) | 1.00 [1.00; 1.00] | 0.38 | ||
| Ferritin (ug/L) | 1.00 [1.00; 1.00] | 0.10 | ||
| Calcium (mmol/L) | 0.89 [0.47; 1.68] | 0.72 | ||
| Phosphorus (mmol/L) | 2.31 [1.04; 5.14] | 0.051 | ||
| Intact PTH (pf/mL) | 1.01 [1.00; 1.01] | 0.003 | ||
| 25OH‐Vitamin D (ng/mL) | 1.00 [0.99; 1.01] | 0.91 | ||
| Soluble ST2 (ng/mL) | 3.46 [1.23; 9.74] | 0.020 | ||
| FGF‐23 (RU/mL) | 2.21 [1.52; 3.22] | <0.001 | 3.15 [1.88; 5.31] | <0.001 |
| Echo study | ||||
| LA volume index (mL/m2) | 1.01 [1.00; 1.02] | 0.17 | ||
| LV ejection fraction (%) | 1.01 [0.98; 1.04] | 0.69 | ||
| LV Endo GLS (%) | 1.00 [0.93; 1.07] | 0.95 | ||
| E wave velocity (m/s) | 1.01 [1.00; 1.02] | 0.002 | 1.01 [1.00; 1.02] | 0.036 |
| E/e′ septal ratio | 1.03 [1.01; 1.05] | 0.018 | ||
| RV/RA gradient (mmHg) | 1.02 [1.00; 1.04] | 0.093 | ||
| RV fractional area change (%) | 0.27 [0.02; 3.11] | 0.29 | ||
| TAPSE | 0.97 [0.93; 1.01] | 0.13 | ||
| cMR study | ||||
| LA volume index (mL/m2) | 1.00 [1.00; 1.01] | 0.31 | ||
| LV EDV index (mL/m2) | 1.00 [0.99; 1.02] | 0.83 | ||
| LV ejection fraction (%) | 1.01 [0.98; 1.04] | 0.55 | ||
| LV mass index (g/m2) | 1.00 [0.99; 1.02] | 0.64 | ||
| RV EDV index (mL/m2) | 1.01 [1.00; 1.02] | 0.031 | ||
| RV ejection fraction (%) | 0.98 [0.95; 1.01] | 0.11 | ||
| Extracellular volume (%) | 1.10 [1.05; 1.15] | <0.001 | ||
| Late gadolinium enhancement | 1.09 [0.99; 1.20] | 0.11 | ||
ACEi, angiotensin‐converting‐enzyme inhibitor; ARB, Angiotensin II receptor blockers; ECV, extracellular volume; EDV, end‐diastolic volume; FGF‐23, fibroblast growth factor 23; GFR, glomerular filtration rate; GLS, global longitudinal strain; hsTnT, high‐sensitivity troponinT; LA, left atrium; LV, left ventricle; NT‐proBNP, N terminal pro brain natriuretuic peptide; PTH, parathormon; RV, right ventricle; ST2, soluble suppression tumourigenicity 2; TAPSE, tricuspid annular plane systolic excursion.